These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 9139464

  • 1. [Enzyme replacement therapy: a new treatment concept in Gaucher disease].
    Beck M, Mengel E, Barone R.
    Wien Klin Wochenschr; 1997 Feb 14; 109(3):81-5. PubMed ID: 9139464
    [Abstract] [Full Text] [Related]

  • 2. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
    Heitner R, Arndt S, Levin JB.
    S Afr Med J; 2004 Aug 14; 94(8):647-51. PubMed ID: 15352589
    [Abstract] [Full Text] [Related]

  • 3. Enzyme replacement therapy for Gaucher disease in Australia.
    Goldblatt J, Szer J, Fletcher JM, McGill J, Rowell JA, Wilson M.
    Intern Med J; 2005 Mar 14; 35(3):156-61. PubMed ID: 15737135
    [Abstract] [Full Text] [Related]

  • 4. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
    Andersson H, Kaplan P, Kacena K, Yee J.
    Pediatrics; 2008 Dec 14; 122(6):1182-90. PubMed ID: 19047232
    [Abstract] [Full Text] [Related]

  • 5. [Diagnosis and therapy of Gaucher disease].
    Ehlen C, Heintges T, Niederau C.
    Med Klin (Munich); 1995 May 15; 90(5):284-90. PubMed ID: 7791695
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.
    Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Zimran A.
    Am J Med; 2002 Aug 01; 113(2):112-9. PubMed ID: 12133749
    [Abstract] [Full Text] [Related]

  • 7. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep 01; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 8. A less costly regimen of alglucerase to treat Gaucher's disease.
    Figueroa ML, Rosenbloom BE, Kay AC, Garver P, Thurston DW, Koziol JA, Gelbart T, Beutler E.
    N Engl J Med; 1992 Dec 03; 327(23):1632-6. PubMed ID: 1435900
    [Abstract] [Full Text] [Related]

  • 9. Alglucerase. A review of its therapeutic use in Gaucher's disease.
    Whittington R, Goa KL.
    Drugs; 1992 Jul 03; 44(1):72-93. PubMed ID: 1379912
    [Abstract] [Full Text] [Related]

  • 10. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.
    Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE.
    N Engl J Med; 1991 May 23; 324(21):1464-70. PubMed ID: 2023606
    [Abstract] [Full Text] [Related]

  • 11. Gaucher's disease: a review.
    Morales LE.
    Ann Pharmacother; 1996 Apr 23; 30(4):381-8. PubMed ID: 8729893
    [Abstract] [Full Text] [Related]

  • 12. Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment.
    Zimran A, Elstein D, Kannai R, Zevin S, Hadas-Halpern I, Levy-Lahad E, Cohen Y, Horowitz M, Abrahamov A.
    Am J Med; 1994 Jul 23; 97(1):3-13. PubMed ID: 8030654
    [Abstract] [Full Text] [Related]

  • 13. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
    Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, Barton NW.
    Blood Cells Mol Dis; 2000 Aug 23; 26(4):285-90. PubMed ID: 11042029
    [Abstract] [Full Text] [Related]

  • 14. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease.
    Hollak CE, Aerts JM, Goudsmit R, Phoa SS, Ek M, van Weely S, von dem Borne AE, van Oers MH.
    Lancet; 1995 Jun 10; 345(8963):1474-8. PubMed ID: 7769902
    [Abstract] [Full Text] [Related]

  • 15. [Alglucerase treatment of type I Gaucher's disease. Preliminary results in Spain. Spanish Group on Gaucher's Disease].
    Pérez-Calvo JI, Giraldo P, Giralt M.
    Sangre (Barc); 1997 Jun 10; 42(3):189-94. PubMed ID: 9381260
    [Abstract] [Full Text] [Related]

  • 16. Extended interval between enzyme therapy infusions for adult patients with Gaucher's disease type 1.
    Pérez-Calvo J, Giraldo P, Pastores GM, Fernández-Galán M, Martín-Nuñez G, Pocoví M.
    J Postgrad Med; 2003 Jun 10; 49(2):127-31. PubMed ID: 12867687
    [Abstract] [Full Text] [Related]

  • 17. [Uveitis masquerade syndrome in Gaucher disease. Causal treatment by alglucerase substitution therapy].
    Dann K, Althaus C, Kersten A, vom Dahl S, Sundmacher R.
    Klin Monbl Augenheilkd; 1998 Dec 10; 213(6):358-61. PubMed ID: 10048015
    [Abstract] [Full Text] [Related]

  • 18. Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.
    Whittington R, Goa KL.
    Pharmacoeconomics; 1995 Jan 10; 7(1):63-90. PubMed ID: 10155294
    [Abstract] [Full Text] [Related]

  • 19. [Response criteria for enzyme substitution in Gaucher disease].
    Berthold F, Sieverts H, Benz-Bohm G, Landwehr P, Harzer K.
    Monatsschr Kinderheilkd; 1992 Oct 10; 140(10):740-4. PubMed ID: 1331780
    [Abstract] [Full Text] [Related]

  • 20. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
    Drelichman G, Ponce E, Basack N, Freigeiro D, Aversa L, Graciela E, Kohan R.
    J Pediatr; 2007 Aug 10; 151(2):197-201. PubMed ID: 17643778
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.